Page last updated: 2024-12-11

elsamicin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

elsamicin A: from actinomycete strain J907-21; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5362259
CHEMBL ID2106409
SCHEMBL ID3988
MeSH IDM0142780

Synonyms (41)

Synonym
elsamicin a
e-87/025
elsamitrucin
bbm-2478a
bmy-28090
bu-2478a
bms-181171
97068-30-9
nsc-369327
bbm 2478a
brn 5214813
elsamitrucinum [inn-latin]
10-o-elsaminosylelsarosylchartarin
elsamitrucine [inn-french]
benzo(h)(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,12-dione, 10-((2-o-(2-amino-2,6-dideoxy-3-o-methyl-alpha-d-galactopyranosyl)-6-deoxy-3-c-methyl-beta-d-galactopyranosyl)oxy)-6-hydroxy-1-methyl-
antibiotic bbm 2478a
2-amino-2,6-dideoxy-3-o-methyl-d-galactose
elsamitrucina [inn-spanish]
elsamitrucin [usan:inn]
bmy 28090
spi 28090
elsamitrucin (usan/inn)
D03977
elsamitrucine
nsc 369327
unii-ztv0fob6nu
ztv0fob6nu ,
elsamitrucinum
elsamitrucina
CHEMBL2106409
DB05129
SCHEMBL3988
benzo(h)(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,12-dione, 10-((2-o-(2-amino-2,6-dideoxy-3-o-methyl-.alpha.-d-galactopyranosyl)-6-deoxy-3-c-methyl-.beta.-d-galactopyranosyl)oxy)-6-hydroxy-1-methyl-
elsamitrucin [usan]
elsamitrucin [inn]
bbm-2478 a
MGQRRMONVLMKJL-KWJIQSIXSA-N
Q5367460
10-(((2s,3r,4s,5s,6r)-3-(((2r,3r,4r,5s,6r)-3-amino-5-hydroxy-4-methoxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4,5-dihydroxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-6-hydroxy-1-methylbenzo[h]chromeno[5,4,3-cde]chromene-5,12-dione
3-[(2s,3r,4s,5s,6r)-3-[(2r,3r,4r,5s,6r)-3-amino-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-8-hydroxy-15-methyl-11,18-dioxapentacyclo[10.6.2.02,7.09,19.016,20]icosa-1(19),2(7),3,5,8,12(20),13,15-octaene-10,17-dione
DTXSID101028137

Research Excerpts

Overview

Elsamicin A is an antitumor antibiotic with fascinating chemical structure. It is a good candidate for pharmaceutical development.

ExcerptReferenceRelevance
"Elsamicin A is an antitumor antibiotic with fascinating chemical structure and a good candidate for pharmaceutical development. "( Product analyses in DNA strand scission by antitumor antibiotic elsamicin A.
Sugiura, Y; Uesugi, M, 1992
)
1.96

Toxicity

ExcerptReferenceRelevance
"Cardiotoxicity, a side-effect that can occur after treatment with an anticancer drug, has severe clinical implications."( In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria.
Bast, A; Haenen, GR; van Acker, FA; van Acker, SA; van der Vijgh, WJ,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (11.54)18.7374
1990's20 (76.92)18.2507
2000's3 (11.54)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (20.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (76.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [NCT00090090]Phase 2114 participants Interventional2004-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]